Ownership and insider activity for Cocrystal Pharma, Inc. (COCP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses.
Price
| Price | $1.14 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-12 | Brosgart Carol L | |||
| 2026-08-05 | FROST PHILLIP MD ET AL | P-Purchase | 10,000 | $10K |
| 2026-08-03 | FROST PHILLIP MD ET AL | P-Purchase | 75,000 | $71K |
| 2026-06-03 | SAPIRSTEIN JAMES | |||
| 2026-02-24 | FROST PHILLIP MD ET AL | P-Purchase | 20,000 | $20K |
| 2026-02-06 | FROST PHILLIP MD ET AL | P-Purchase | 50,000 | $47K |
| 2026-01-09 | Kornberg Roger D. | A-Award | 24,615 | $27K |
| 2026-01-09 | PFENNIGER RICHARD C JR | A-Award | 16,410 | $18K |
| 2026-01-09 | Lee Sam | A-Award | 49,229 | $54K |
| 2026-01-09 | Hassan Fred | A-Award | 16,410 | $18K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.6M | $748000 | $2.7M | $7.4M | $33.0M | $58.7M | $37.1M | $26.4M | $9.9M | $7.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $1.3M | $1.3M | 0 | $644000 | $556000 | 0 | $716000 | $890000 | $1.2M | $706000 |
| Inventory | 0 | $29000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $5.5M | $2.2M | $2.9M | $8.3M | $34.0M | $59.3M | $40.2M | $29.1M | $11.6M | $8.1M |
| Property, Plant & Equipment | $280000 | $119000 | $384000 | $1.1M | $1.1M | $931000 | $616000 | $2.1M | $1.8M | $1.5M |
| Goodwill | $65.2M | $65.2M | $65.2M | $19.1M | $19.1M | $19.1M | 0 | 0 | 0 | 0 |
| Intangible Assets | $53.9M | $53.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $124.9M | $121.4M | $68.6M | $28.5M | $54.2M | $79.4M | $40.8M | $31.3M | $13.5M | $9.7M |
| Accounts Payable | $563000 | $494000 | $616000 | $1.5M | $657000 | $578000 | $614000 | $1.2M | $1.5M | $890000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.0M | $1.4M | $1.6M | $2.3M | $1.4M | $1.5M | $1.2M | $3.3M | $2.4M | $2.2M |
| Long-term Debt | 0 | $1.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $22.6M | $16.0M | $1.7M | $2.8M | $1.7M | $1.8M | $1.3M | $4.9M | $3.9M | $3.4M |
| Retained Earnings | -$137.4M | -$138.0M | -$187.1M | -$235.3M | -$244.9M | -$259.1M | -$297.9M | -$315.9M | -$333.4M | -$342.2M |
| Total Equity | $102.3M | $105.4M | $66.9M | $25.7M | $52.5M | $77.5M | $39.6M | $26.4M | $9.5M | $6.3M |
| Total Debt | 0 | $1.0M | $331000 | $817000 | $596000 | $534000 | $297000 | $1.9M | $1.8M | $1.5M |
| Net Debt | -$3.6M | $259000 | -$2.4M | -$6.6M | -$32.4M | -$58.2M | -$36.8M | -$24.5M | -$8.1M | -$5.5M |
| Working Capital | $3.4M | $770000 | $1.4M | $6.0M | $32.7M | $57.8M | $39.0M | $25.8M | $9.2M | $5.9M |
Financial Health
| Debt / Equity | 1.28 |
| Current Ratio | 1.24 |
Profitability
| Return on Equity | -207.47% |
| Return on Invested Capital | -423.90% |
| Return on Assets | -213.77% |
| Gross Margin | 205.76% |
| Operating Margin | -3063.64% |
| Net Margin | -3011.52% |
Related companies: BOLT · BRTX · CING · DWTX · EVGN · IMNN · IMRN
Explore sector: Healthcare · Biotechnology
More sections of COCP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks